AstraZeneca’s Baxdrostat Achieves Pivotal Phase 3 Success for Hypertension, Validating $1.3B CinCor Acquisition

AstraZeneca’s experimental blood pressure drug, baxdrostat, significantly lowered systolic blood pressure compared to placebo in a Phase 3 trial involving patients with uncontrolled or treatment-resistant hypertension135.

The pivotal trial enrolled 796 patients, testing 1 mg and 2 mg daily doses of baxdrostat or placebo for 12 weeks, and met its primary endpoint of statistically significant, clinically meaningful reduction in mean seated systolic blood pressure5.

Baxdrostat also met all secondary endpoints, including blood pressure reductions in resistant hypertension subgroups and a higher proportion of patients achieving systolic BP under 130 mmHg at week 1215.

The drug was generally well tolerated, showing a favorable safety profile in both short-term and year-long assessments15.

Baxdrostat targets aldosterone synthase (CYP11B2) to lower aldosterone levels, addressing a hormonal pathway that has seen little innovation in two decades35.

AstraZeneca acquired CinCor Pharma, the original developer of baxdrostat, for $1.3 billion in 2023, betting on the drug’s potential to address the large hypertension market35.

Hypertension affects 1.3 billion people globally, and analysts estimate a $70 billion addressable market in the U.S. alone for this drug3.

AstraZeneca plans to share full data at the European Society of Cardiology Congress and with regulatory authorities worldwide15.

Sources:

1. https://www.biopharmadive.com/news/astrazeneca-baxdrostat-hypertension-study-results-cincor/752928/

3. https://www.morningstar.com/news/marketwatch/2025071446/astrazeneca-shares-show-signs-of-life-after-successful-trials-of-hypertension-drug

5. https://www.fiercebiotech.com/biotech/astrazenecas-13b-bet-cinccors-blood-pressure-med-appears-pay-phase-3-win